Alpelisib has been approved by the FDA for PIK3CA-mutated HR+ HER2- BC [21], along with its companion diagnostic test, therascreen® PIK3CA RGQ PCR Kit (QIAGEN GmbH, QIAGEN Strasse 1, Hilden, Germany). The gene discussed is PIK3CA; the disease is breast cancer.